Organon & Co. (OGN) Competitors

$13.36 +0.03 (+0.19%)

As of 01:57 PM Eastern

OGN vs. ASND, BBIO, SMMT, RDY, and ELAN

Should you buy Organon & Co. stock or one of its competitors? MarketBeat compares Organon & Co. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organon & Co. include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Organon & Co. compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Ascendis Pharma A/S presently has a consensus price target of $291.50, suggesting a potential upside of 20.14%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 14.70%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat Ascendis Pharma A/S's score of 0.96 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Organon & Co. has higher revenue and earnings than Ascendis Pharma A/S. Organon & Co. is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.48	-$258M	$8.67	27.99
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37

Ascendis Pharma A/S has a net margin of 57.87% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Organon & Co.	3.99%	99.95%	6.22%

Ascendis Pharma A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

77.4% of Organon & Co. shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Organon & Co. on 10 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

BridgeBio Pharma currently has a consensus price target of $88.19, indicating a potential upside of 26.96%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 14.70%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	27.10	-$724.93M	-$3.74	N/A
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37

Organon & Co. has a net margin of 3.99% compared to BridgeBio Pharma's net margin of -124.42%. Organon & Co.'s return on equity of 99.95% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Organon & Co.	3.99%	99.95%	6.22%

BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 38 more articles in the media than Organon & Co.. MarketBeat recorded 43 mentions for BridgeBio Pharma and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat BridgeBio Pharma's score of 0.54 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	11 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Organon & Co. beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Summit Therapeutics?

Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Organon & Co. has a net margin of 3.99% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Summit Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Summit Therapeutics and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat Summit Therapeutics' score of 1.17 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 14.70%. Summit Therapeutics has a consensus target price of $27.58, suggesting a potential upside of 52.94%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50

Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Organon & Co. has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, suggesting that its stock price is 225% less volatile than the broader market.

Summary

Organon & Co. beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.28%	8.25%
Organon & Co.	3.99%	99.95%	6.22%

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat Dr. Reddy's Laboratories' score of -0.47 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.15	$663M	$0.77	17.53
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories presently has a consensus target price of $16.90, suggesting a potential upside of 25.23%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 14.70%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, equities research analysts clearly believe Dr. Reddy's Laboratories is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays out 9.1% of its earnings in the form of a dividend. Organon & Co. pays out 8.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Dr. Reddy's Laboratories beats Organon & Co. on 10 of the 18 factors compared between the two stocks.

How does Organon & Co. compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Organon & Co. has a net margin of 3.99% compared to Elanco Animal Health's net margin of -4.95%. Organon & Co.'s return on equity of 99.95% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Organon & Co.	3.99%	99.95%	6.22%

Elanco Animal Health currently has a consensus target price of $28.20, indicating a potential upside of 29.33%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 14.70%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.31	-$232M	-$0.50	N/A
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37

In the previous week, Elanco Animal Health had 10 more articles in the media than Organon & Co.. MarketBeat recorded 15 mentions for Elanco Animal Health and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat Elanco Animal Health's score of 0.41 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Organon & Co. beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$3.51B	$8.33B	$6.30B	$23.00B
Dividend Yield	0.60%	2.92%	2.79%	4.07%
P/E Ratio	14.37	21.90	20.92	28.45
Price / Sales	0.56	16.08	551.58	24.33
Price / Cash	2.30	83.95	42.94	25.11
Price / Book	3.89	5.62	9.87	4.76
Net Income	$187M	$183.43M	$3.55B	$1.06B
7 Day Performance	0.15%	0.73%	-0.20%	-0.51%
1 Month Performance	53.62%	5.78%	1.48%	1.98%
1 Year Performance	66.02%	5.06%	41.00%	25.22%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	3.1453 of 5 stars	$13.37 +0.2%	$11.40 -14.7%	+58.1%	$3.51B	$6.22B	14.37	10,000	Positive News Ex-Dividend
ASND Ascendis Pharma A/S	3.8895 of 5 stars	$228.71 +3.5%	$291.56 +27.5%	+50.8%	$13.78B	$814.57M	N/A	1,189	Positive News Earnings Report Analyst Forecast Insider Trade
BBIO BridgeBio Pharma	3.4636 of 5 stars	$68.99 +0.6%	$87.71 +27.1%	+106.3%	$13.42B	$502.08M	N/A	400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
SMMT Summit Therapeutics	3.2765 of 5 stars	$16.98 +5.4%	$27.58 +62.4%	-23.6%	$12.51B	N/A	N/A	110	Positive News
RDY Dr. Reddy's Laboratories	3.3076 of 5 stars	$13.33 -2.9%	$16.90 +26.8%	-7.9%	$11.45B	$3.81B	17.31	27,811	News Coverage Earnings Report Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. ASND, BBIO, SMMT, RDY, and ELAN

How does Organon & Co. compare to Ascendis Pharma A/S?

Summary

How does Organon & Co. compare to BridgeBio Pharma?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. ASND, BBIO, SMMT, RDY, and ELAN

How does Organon & Co. compare to Ascendis Pharma A/S?

Do analysts prefer ASND or OGN?

Does the media favor ASND or OGN?

Which has better valuation & earnings, ASND or OGN?

Is ASND or OGN more profitable?

Which has more volatility and risk, ASND or OGN?

Do insiders and institutionals hold more shares of ASND or OGN?

Summary

How does Organon & Co. compare to BridgeBio Pharma?

Do analysts recommend BBIO or OGN?

Which has better earnings and valuation, BBIO or OGN?

Is BBIO or OGN more profitable?

Which has more risk & volatility, BBIO or OGN?

Do insiders and institutionals have more ownership in BBIO or OGN?

Does the media prefer BBIO or OGN?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Is OGN or SMMT more profitable?

Does the media prefer OGN or SMMT?

Do analysts rate OGN or SMMT?

Which has higher valuation & earnings, OGN or SMMT?

Do institutionals & insiders hold more shares of OGN or SMMT?

Which has more volatility and risk, OGN or SMMT?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Is RDY or OGN more profitable?

Which has more risk and volatility, RDY or OGN?

Does the media prefer RDY or OGN?

Which has stronger earnings and valuation, RDY or OGN?

Do insiders and institutionals hold more shares of RDY or OGN?

Do analysts recommend RDY or OGN?

Is RDY or OGN a better dividend stock?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Is ELAN or OGN more profitable?

Do analysts recommend ELAN or OGN?

Which has more risk and volatility, ELAN or OGN?

Which has stronger earnings & valuation, ELAN or OGN?

Does the media refer more to ELAN or OGN?

Do institutionals and insiders believe in ELAN or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools